睿知中国疾病研究地图
候选清单0

正在招募B 细胞急性淋巴细胞白血病II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06179524,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 未注明 至 25 岁;性别:不限

    登记记录的入选字段

  2. Bone marrow examination confirmed the diagnosis of B-ALL, and meet one of the following conditions: Relapsed B-ALL:1)Relapse within 12 months of the first remission;2)Recurrence occurring again more than 12 months after the first remission,, relapsed or not responded after first-line/multi-line salvage chemotherapy;3) Experienced two or more bone marrow recurrences; 4) recurrence after autologous or allogeneic hematopoietic stem cell transplantation; Refractory B-ALL:1)failed to achieve complete remission after 2 cycles of standard induction chemotherapy.

    入选标准第 3 条

    Ph+ALL patients are eligible:1)Relapsed or refractory after receiving at least two Tyrosine kinase inhibitors (TKI) treatments;If Ph+ALL patients with t315i mutation are resistant to first- and second-generation TKIs, in the absence of effective TKI therapy, patients are not required to receive at least two TKIs;2)cannot tolerate TKI treatment;3)Presence of contraindications to TKI therapy.

    入选标准第 4 条

    Participants who have received HSCT within 3 months before screening or Presence of grade 2 to 4 active graft-versus-host disease (GVHD), and those who have received systemic drug therapy for GVHD within 4 weeks before infusion.

    排除标准第 8 条

    Received the following anti-tumor therapy before apheresis:1)Received any chemotherapy, targeted therapy, etc. within 4 weeks or at least 5 half-lives (whichever is shorter);2)Radiotherapy within 14 days;3)Intrathecal treatment within 7 days;4) Received a donor lymphocyte transfusion (DLI) within 4 weeks; 5)Received Blinatumomab within 14 days.

    排除标准第 9 条

    participated in other interventional clinical studies (received active trial drug treatment) within 3 months before screening, or intend to participate in another clinical trial or receive another anti-tumor therapy.

    排除标准第 17 条

  3. Karnofsky(age≥16 years)performance status≥70 or Lansky(age<16 years)performance status≥50.

    入选标准第 8 条

  4. Any of the following applies:1)Hepatitis B surface antigen (HBsAg) positive or HBV-DNA quantity is higher than the upper limit of normal value;2)Hepatitis C virus antibody (HCV Ab) is positive and HCV RNA quantification is higher than the upper limit of normal values;3)Positive for human immunodeficiency virus antibody (HIV-Ab);4)EB virus DNA quantification is higher than the upper limit of normal values;5)Cytomegalovirus DNA quantification is higher than the upper limit of normal values.

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06179524,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation in clinical trial, The Participants or his legal guardian is fully understands this clinical trial and signs the Informed Consent Form (ICF); Willing to follow and be able to complete all trial procedures.
  2. Age≤25 years old at the time of screening, regardless of gender.
  3. Bone marrow examination confirmed the diagnosis of B-ALL, and meet one of the following conditions: Relapsed B-ALL:1)Relapse within 12 months of the first remission;2)Recurrence occurring again more than 12 months after the first remission,, relapsed or not responded after first-line/multi-line salvage chemotherapy;3) Experienced two or more bone marrow recurrences; 4) recurrence after autologous or allogeneic hematopoietic stem cell transplantation; Refractory B-ALL:1)failed to achieve complete remission after 2 cycles of standard induction chemotherapy.
  4. Ph+ALL patients are eligible:1)Relapsed or refractory after receiving at least two Tyrosine kinase inhibitors (TKI) treatments;If Ph+ALL patients with t315i mutation are resistant to first- and second-generation TKIs, in the absence of effective TKI therapy, patients are not required to receive at least two TKIs;2)cannot tolerate TKI treatment;3)Presence of contraindications to TKI therapy.
  5. Bone marrow (BM) or peripheral blood (PB) tumor cells were measured to express CD19 at screening.
  6. Bone marrow blasts ≥ 5% at screening.
  7. Adequate organ function and must meet the following criteria: Alanine aminotransferase (ALT) ≤ 5 ×Upper limit of normal value(ULN);Total serum bilirubin ≤ 2.0 ×ULN((for Gilbert syndrome, total bilirubin≤3.0×ULN);in non-oxygen state, No > grade 1 dyspnea, Blood oxygen saturation > 95%;left ventricular ejection fraction(LVEF) ≥ 50%;Serum creatinine≤1.5 × ULN;
  8. Karnofsky(age≥16 years)performance status≥70 or Lansky(age<16 years)performance status≥50.
  9. Life expectancy ≥ 12 weeks.
  10. Adequate venous access (for apheresis) and no other contraindications to apheresis.
  11. Negative blood/urine pregnancy test in women of childbearing potential before screening and within 3 days prior to cell infusion, and any male and female patients of childbearing potential must agree to use an effective method of contraception throughout the study and for at least 2 years after CAR-T-19 infusion. In the judgment of the investigator, a patient of childbearing potential means that he/she is biologically capable of having children and having a normal sexual life.
  12. For Participants who have previously undergone allogeneic hematopoietic stem cell transplantation, CAR-T-19 cell preparation is performed using their previous donor peripheral blood, and the donor needs to meet the following conditions:1)Have donated bone marrow/hematopoietic stem cells as a transplant donor for the patient;2)Age ≥8 years at screening;3)Voluntary participation in clinical studies; the donor (and legal guardian, if applicable) am fully aware of and informed about this trial and have signed an informed consent form (ICF); Willing to follow and be able to complete all trial procedures;4)Have adequate venous access (for apheresis or venous blood collection) and no other contraindications to apheresis; 5) The etiological test results do not correspond to any of the exclusion criteria outlined in item 12. 6) Women of childbearing age have negative blood and urine pregnancy tests.7) Systemic glucocorticoid therapy is prohibited within one week prior to apheresis, with the exception of physiologically replacement doses of glucocorticoids (0.5 mg/kg/day of prednisone or equivalent doses of other corticosteroids).8) There are no cases of uncontrolled fungal, bacterial, viral, or other infections requiring intravenous treatment.

排除标准:Exclusion Criteria:

  1. Isolated extra-medullary disease relapse .
  2. Participants with genetic syndromes, Patients with Down Syndrome will not be excluded.
  3. Participants with Burkitt's lymphoma/leukemia.
  4. Participants with active central nervous system disease.
  5. Active central nervous system leukemia at screening(Defined as CNS-3 and CNS-2 grades with neurological symptoms as defined by NCCN guidelines and judged by the investigator to be active central leukemia).
  6. Participants with a history of other malignant tumors or other malignant tumors at the same time (excluding fully treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, thyroid cancer, ductal carcinoma in situ after radical resection).
  7. have or suspected to have fungal, bacterial, viral or other infections that are uncontrollable or require intravenous treatment.
  8. Participants who have received HSCT within 3 months before screening or Presence of grade 2 to 4 active graft-versus-host disease (GVHD), and those who have received systemic drug therapy for GVHD within 4 weeks before infusion.
  9. Received the following anti-tumor therapy before apheresis:1)Received any chemotherapy, targeted therapy, etc. within 4 weeks or at least 5 half-lives (whichever is shorter);2)Radiotherapy within 14 days;3)Intrathecal treatment within 7 days;4) Received a donor lymphocyte transfusion (DLI) within 4 weeks; 5)Received Blinatumomab within 14 days.
  10. Participants who have been treated with systemic glucocorticoids within 1 week before apheresis, physiological replacement doses of steroids are allowed.
  11. Long-acting G-CSF is prohibited within 21 days and short-acting G-CSF is prohibited within 7 days before apheresis.
  12. Any of the following applies:1)Hepatitis B surface antigen (HBsAg) positive or HBV-DNA quantity is higher than the upper limit of normal value;2)Hepatitis C virus antibody (HCV Ab) is positive and HCV RNA quantification is higher than the upper limit of normal values;3)Positive for human immunodeficiency virus antibody (HIV-Ab);4)EB virus DNA quantification is higher than the upper limit of normal values;5)Cytomegalovirus DNA quantification is higher than the upper limit of normal values.
  13. Those who have received CAR-T therapy with any target.
  14. Allergy to albumin and aminoglycoside antibiotics.
  15. Received live vaccine within 6 weeks before screening.
  16. Participants after organ transplantation (except hematopoietic stem cell transplantation).
  17. participated in other interventional clinical studies (received active trial drug treatment) within 3 months before screening, or intend to participate in another clinical trial or receive another anti-tumor therapy.
  18. Other investigators deem it inappropriate to participate in the study.

引自 ClinicalTrials.gov, NCT06179524, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06179524,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06179524